Safety and effectiveness of combination versus monotherapy with immune checkpoint inhibitors in patients with preexisting autoimmune diseases.

17.1 months, P = .53), however, the differences did not reach statistical significance ( Table 4 and Figure 2 ).

also in 111,027 other papers

Specifically, our results showed a trend for better PFS with ICI combination therapy for patients with melanoma, but not for patients with lung cancer, so we cannot draw conclusions across cancer diagnoses.

also in 53,322 other papers